4892-10-8

Basic information

• Product Name: N-(benzyloxycarbonyl)phenylalanylphenylalanine methyl ester
• Synonyms: N-(benzyloxycarbonyl)phenylalanylphenylalanine methyl ester
• CAS NO: 4892-10-8
• Molecular Formula: C₂₇H₂₈N₂O₅
• Molecular Weight: 460.52
• Mol File: 4892-10-8.mol
• Article Data: 29

Chemical Properties

• Boiling Point: 687.7°C at 760 mmHg
• Flash Point: 369.7°C
• Appearance: /
• Density: 1.206g/cm³
• Vapor Pressure: 9.19E-19mmHg at 25°C
• Refractive Index: 1.584
• CAS DataBase Reference: N-(benzyloxycarbonyl)phenylalanylphenylalanine methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-(benzyloxycarbonyl)phenylalanylphenylalanine methyl ester(4892-10-8)
• EPA Substance Registry System: N-(benzyloxycarbonyl)phenylalanylphenylalanine methyl ester(4892-10-8)

Safety Data

• Hazardous Substances Data: 4892-10-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C27H28N2O5/c1-33-26(31)24(18-21-13-7-3-8-14-21)28-25(30)23(17-20-11-5-2-6-12-20)29-27(32)34-19-22-15-9-4-10-16-22/h2-16,23-24H,17-19H2,1H3,(H,28,30)(H,29,32)/t23-,24-/m0/s1

Upstream product

• 2577-90-4 methyl (2S)-2-amino-3-phenylpropanoate 
• 1161-13-3 N-Cbz-L-Phe 
• 7524-50-7 methyl (2S)-2-amino-3-phenylpropanoate hydrochloride 
• 2578-84-9 N-benzyloxycarbonyl-L-phenylalanine p-nitrophenyl ester 
• 87072-42-2 Z-L-phenylalanine DCHA salt 
• 26055-07-2 Z-Phe-OBT 
• 96452-61-8 N-(Benzyloxycarbonyl)-L-phenylalanin-2-pyridylester 
• 63-91-2 L-phenylalanine 
• 501-53-1 benzyl chloroformate 
• 96452-48-1 benzyl pyridin-2-yl carbonate 
• 101-83-7 N-cyclohexyl-cyclohexanamine 
• 1059596-58-5 N-Cbz-L-phenylalanine p-tolylthiol ester 
• 3397-32-8 N-(benzyloxycarbonyl)-phenylalanine-N-hydroxysuccinimide ester 
• 117999-37-8 Z-ΔPhe-(S)-Phe-OMe 

Downstream Products

• 13122-91-3 N-benzyloxycarbonyl-L-phenylalanyl-L-phenylalanine 
• 13082-29-6 L-phenylalanyl-L-phenylalanine methyl ester 
• 2862-51-3 (3S,6S)-3,6-dibenzylpiperazine-2,5-dione 
• 2562-48-3 N-acetyl-L-phenylalanyl-L-phenylalanine methylester 
• 99260-33-0 H-Phe-Phe-OMe*HOAc 
• 69193-13-1 Cbz-L-Phe-L-Leu-NH₂ 
• 126028-19-1 N-cbz-L-Phe-L-Phe-L-Leu-NH₂ 
• 61123-13-5 pyroglutamyl-phenylalanyl-phenylalanine-glycyl-leucyl-methionine amide 
• 51165-07-2 glutamyl-phenylalanyl-phenylalanyl-glycyl-leucyl-methionine amide 
• 77511-07-0 t-butyloxycarbonyl-glutamyl-phenylalanyl-phenylalanine 
• 64699-01-0 t-butyloxycarbonyl-glutamyl-phenylalanyl-phenylalanyl-glycyl-leucyl-methionine amide 
• 77511-08-1 pyroglutamyl-phenylalanyl-phenylalanine methyl ester 
• 77338-34-2 pyroglutamyl-phenylalanyl-phenylalanine 
• 77511-06-9 t-butyloxycarbonyl-glutamyl-phenylalanyl-phenylalanine methyl ester 

Relevant articles and documents

An efficient amide-forming reaction using tributyltrichloromethylphosphonium chloride

An efficient and expeditious amide-forming reaction is described via a combination of tributylphosphine and carbon tetrachloride (in situ generation of tributyltrichloromethylphosphonium chloride) in the absence of tertiary amines.

Mechanochemical Synthesis of Dipeptides Using Mg-Al Hydrotalcite as Activating Agent under Solvent-Free Reaction Conditions

Given the high demand for green and sustainable synthetic methods for the formation of amides and peptidic bonds, herein we report the efficient, solvent-free mechanochemical synthesis of dipeptides from N-protected amino acids and amino acid methyl ester

Synthesis, bioactivity, docking and molecular dynamics studies of furan-based peptides as 20s proteasome inhibitors

Proteasome inhibitors are promising compounds for a number of therapies, including cardiovascular and eye diseases, diabetes, and cancers. We previously reported a series of furanbased peptidic inhibitors with moderate potencies against the proteasome b5 subunit, hypothesizing that the C-terminal furyl ketone motif could form a covalent bond with the catalytic residue, threonine 1. In this context, we describe further optimizations of the furan-based peptides, and a series of dipeptidic and tripeptidic inhibitors were designed and synthesized, aiming at improved potency and better solubility. Most of the tripeptidic inhibitors demonstrated improved potency and selectivity as b5 subunit inhibitors in both enzymatic and cellular assays, and good antineoplastic activities in various tumor cell lines were also observed. However, no inhibitory effects were observed for the dipeptidic compounds, which led us to presume that a noncovalent binding mode is adopted. Docking studies and molecular dynamics simulations were carried out to verify this presumption, with results showing that the distance between the furyl ketone motif and Thr1 is slightly too long to form covalent bond.